Introduction {#j_jomb-2018-0020_s_001}
============

The signs and symptoms of thyroid diseases, especially subclinical hypothyroidism (SCH), are neither sensitive nor specific, so diagnosis mainly depends on a laboratory thyroid function tests (TFT). Therefore, the distinction between a normal and an abnormal TFT result is critical in the recognition of thyroid disorders. The prevalence of thyroid dysfunction is 5--10 times higher in women compared to men, which might be explained by range of factors ([@j_jomb-2018-0020_ref_001]). In the female population, thyroid hormones play an important role in normal ovarian function ([@j_jomb-2018-0020_ref_002]), so reference limits for women in their reproductive period could be of help, especially in fertility challenged ones. ([@j_jomb-2018-0020_ref_003]) The measurement of the thyroid-stimulating hormone (TSH) is the most sensitive and widely used as a »first-step« screening test for primary thyroid disorders ([@j_jomb-2018-0020_ref_004]). The determination of its reference limits (especially the upper limit) is challenging for many different reasons and has been a subject of ongoing debate for the last fifteen years. Median population thyrotropin values are usually between 1--1.5 mU/L ([@j_jomb-2018-0020_ref_005], [@j_jomb-2018-0020_ref_006]) but they do not have a normal distribution, and rather display a right skewed one, with a long tail towards higher values. In 2005, Wartofsky and Dickey ([@j_jomb-2018-0020_ref_007]) advocated the lowering of the upper TSH limit from 4--5 mU/L to 2.5 mU/L since more than 95% of the normal population has a value below this limit. They suggested that persons with higher values are at risk of early thyroid failure. In contrast, some authors point out the huge medical and economical effect of the proposed change, leading to a nearly 4-fold increase in the prevalence of hypothyroidism ([@j_jomb-2018-0020_ref_008], [@j_jomb-2018-0020_ref_009]) and the adverse health effects of thyroxin treatment ([@j_jomb-2018-0020_ref_010], [@j_jomb-2018-0020_ref_011]).

The difficulties in the upper TSH limit determination are partly caused by differences in the TSH reference values established in some of the studies conducted so far ([@j_jomb-2018-0020_ref_012], [@j_jomb-2018-0020_ref_013], [@j_jomb-2018-0020_ref_014], [@j_jomb-2018-0020_ref_015]). These discrepancies can be partially explained by different preanalytical and analytical factors. Preanalytical influences are related to subject selection criteria, the age of the participants ([@j_jomb-2018-0020_ref_016]) and the time period of the sample collection ([@j_jomb-2018-0020_ref_017]). The iodine status of the population is another possible factor affecting TFT reference values, especially thyrotropin ones ([@j_jomb-2018-0020_ref_018]) and it changes with ageing. The Balkan region has been an iodine deficient area, but in our country the process of salt iodization started in the 1950s, so that deficiency was eradicated and according to the results of the most recent study conducted in 2007 -- intake was adequate ([@j_jomb-2018-0020_ref_019]).

According to some data, in circumstances of iodine sufficiency, general population TSH values tend to be higher ([@j_jomb-2018-0020_ref_014], [@j_jomb-2018-0020_ref_020]) and increase with age ([@j_jomb-2018-0020_ref_014], [@j_jomb-2018-0020_ref_020], [@j_jomb-2018-0020_ref_021]) in contrast to iodine deficient areas ([@j_jomb-2018-0020_ref_005], [@j_jomb-2018-0020_ref_022], [@j_jomb-2018-0020_ref_023], [@j_jomb-2018-0020_ref_024]). So, if population specific reference values are not used, this could lead to the incorrect classification of elderly patients regarding thyroid function, in terms of subclinical hypothyroidism in particular. The exact mechanisms of the TSH change with ageing have not yet been clarified.

The analytical factors contributing to the differences in reference values are related to the lack of standardization, differences in the matrix of the calibrators and the specificity of the antibodies in the assays used for the determination of TFT (<http://www.acb.org.uk> docs/tftguidelinefinal -- last accessed 8 January 2018)). As a consequence, the bias between assays from different manufacturers is very noticeable but the Clinical Society's guidelines still do not take it into account.

The focus of our research was to determine accurate TSH, free thyroxin (fT4) and free triiodothyronine (fT3) reference values in the female population between the ages of 20 and 69 by implementing strict reference population selection criteria. Since some data suggest a change in thyrotropin levels with ageing, we aimed to determine the age-related change in this population in order to investigate its relevance and impact on the laboratory diagnosis of subclinical hypothyroidism, in terms of both under-diagnosis and over-diagnosis in different age groups. In addition, by evaluating the changes in TFT against age we aimed to contribute to research in to the possible mechanisms causing this alteration. In order to determine the impact of method related variability on TFT values, we compared results of three different, commonly used assays.

Materials and Methods {#j_jomb-2018-0020_s_002}
=====================

Subjects {#j_jomb-2018-0020_s_002_s_001}
--------

The study population was randomly selected and evaluated among female subjects, aged between 20 and 69, who attended a clinical laboratory over two consecutive years to perform routine laboratory tests, as a part of their health checkup. All the subjects who voluntarily agreed to participate were self-reported as healthy and completed a questionnaire that included the participant's name, date of birth, medical history, their personal and family history of thyroid diseases and any current medications. The Ethics Committee of the Clinical Centre of Montenegro approved the study and all the subjects gave written informed consent.

According to the National Academy of Clinical Biochemistry (NACB) Guidelines for the Diagnosis and Monitoring of Thyroid Diseases ([@j_jomb-2018-0020_ref_025]) and similar recommendations issued by the Association of Clinical Biochemistry and Laboratory Medicine (ACB) and the British Thyroid Association (BTA) (http:// [www.acb.org.uk](http://www.acb.org.uk) docs/tftguidelinefinal.pdf (last accessed 8 January 2017)) in 2006 »reference ranges should be established using specimens collected between 0800h and 1800h and using 95% confidence limits from log transformed data, the reference population should have no personal or family history of thyroid dysfunction, be on no medication known to alter TSH and have no thyroid antibodies detectable by a sensitive assay«. The exclusion criteria in our study were: a personal and/or family history of thyroid disease, positive thyroglobulin and/or thyroid peroxidase antibodies, taking medicine affecting thyroid function (oral contraceptives, estrogen, glucocorticoids, anti-epileptic drugs, amiodarone, and lithium), a diagnosis or a suspected case of polycystic ovarian syndrome (PCOS), a history of severe non-thyroid illness, pregnancy and breast feeding. Those subjects with serum values of TSH\<0.1 mU/L or TSH\>10.0 mU/L were not further analyzed as these results indicate a high probability of thyroid dysfunction ([@j_jomb-2018-0020_ref_026]).

The women included in the study were divided in to five age-related groups: 20--29, 30--39, 40--49, 50--59 and 60--69 years of age.

Laboratory measurements {#j_jomb-2018-0020_s_002_s_002}
-----------------------

The blood samples were collected between 7:00 -- 9:00 AM, after an overnight fast to avoid diurnal variation which has been found to have a significant and considerable impact on TSH values ([@j_jomb-2018-0020_ref_015]). After centrifugation at 3000 RPM for 10 minutes, the serum levels of TSH, fT4, fT3, thyroid peroxidase anti bodies (TPOAb) and thyroglobulin antibodies (TgAb) were measured on the same day using an immuno chemiluminiscent assay on the Architect i2000 platform (Abbott Laboratories, Diagnostic Division, Abbott Park, IL, USA). The total (within-laboratory) precision for all controls was less than or equal to 6% for TSH, 7.2% for fT3, 5.5% for fT4, 5.5% for TPOAb and 3.7% for TgAb. The reference intervals provided by the manufacturer for TSH are 0.35--4.94 mU/L, 9.5-19.0 pmol/L for fT4and 2.5-- 5.7 pmol/L for fT3. According to the package, inserts values of TPOAb lower than 5.6 IU/mL and TgAb below 4.1mU/L are considered antibody negative.

Our subset of 80 samples were further analyzed on a Cobas e411 (Roche Diagnostic, GmbH, Penzberg, Germany) and an Immulite 2000XPI (Siemens Healthcare GmBH, Erlangen, Germany). TSH, fT3 and fT4 were measured, within-run imprecision determined for all the assays.

Statistical analysis {#j_jomb-2018-0020_s_002_s_003}
--------------------

The Kolmogorov-Smirnov method was used to test for the normality of the TFT distributions. Since the TSH, logTSH, fT3 and fT4 values were not normally distributed in the tested population all the results of the descriptive statistics are presented by nonparametric values. The Mann-Whitney test and Kruskal-Wallis test were used to compare the TFT values in different subpopulations. The range between the 2.5^th^ and the 97.5^th^ percentile was used to determine the reference intervals. Assays from different manufacturers were compared using the line of best fit by last square linear regression and Bland-Altman agreement method. Pearson chi test for categorical variables was used. A *p* value \< 0.05 was considered statistically significant. The statistical analyses were performed using an SPSS version 20.0.

Results {#j_jomb-2018-0020_s_003}
=======

A total of 946 subjects met the selection criteria before the measurement of the level of thyroid antibodies. One hundred and fifty-six subjects (16.5%) with positive TPOAb and/or TgAb were further excluded from the reference population (*[Figure 1](#j_jomb-2018-0020_fig_001){ref-type="fig"}*). The overall TSH 2.5^th^ and 97.5^th^ percentiles were 0.44 mU/L and 4.13 mU/L. The reference range for fT3 was 3.3--5.8 pmol/L, and for fT4 it was 10.7-- 18.0 pmol/L. The median, inter quartile range and the 2.5^th^ and 97.5^th^ percentiles of TFT for the five age-related groups are summarized in *[Table I](#j_jomb-2018-0020_tab_001){ref-type="table"}*.

###### 

TSH, fT3 and fT4 concentrations in different age-related groups.

  Age group         TSH (mU/L)    fT3 (pmol/L)   fT4 (pmol/L)                                                   
  ----------- ----- ------------- -------------- -------------- ----------- ------ ------ ------------- ------- -------
  20--29      172   (1.36 0.99)   0.31           3.21           4.6 (0.9)   3.30   5.80   13.1 (2.0)    10.70   17.53
  30--39      198   (1.37 1.21)   0.37           3.60           4.6 (0.9)   3.20   5.70   13.1 (1.6)    10.59   16.11
  40--49      157   (1.44 1.24)   0.42           4.20           4.5 (0.9)   3.30   6.30   13.2 (2.1)    10.40   18.10
  50--59      133   (1.54 1.10)   0.56           4.43           4.7 (0.8)   3.30   5.80   14.0 (2.32)   10.70   18.14
  60--69      130   (2.04 1.34)   0.69           5.07           4.6 (0.7)   3.20   6.50   14.7 (3.0)    11.01   19.08

interquartile range

Median TSH progressively increased with age, with the first significant increase in the 50--59 years

![Flow-chart showing selection criteria of female subjects.](jomb-38-022-g001){#j_jomb-2018-0020_fig_001}

![TSH distribution in the youngest and oldest group.](jomb-38-022-g002){#j_jomb-2018-0020_fig_002}

of age group. The median TSH value, being 2.04 mU/L, was significantly higher in the oldest group compared to all the other groups (p\<0.01). No statistically significant differences in the serum values of free triiodothyronine were observed between any of the groups (p=0.17). Free thyroxin values were significantly higher in the two oldest groups compared to first, second and third age-related group (p\<0.01).

In order to determine the diagnostic relevance of these population specific and age-related TSH upper reference limits, the percentages of females categorized differently compared to the value proposed by manufacturer (4.94 mU/L) were calculated. When using the age-related 97.5 percentile, the percentage of reclassification from normal to abnormal was highest in the 20--29 years of age group (5.2%, p\<0.05), and in the age band 30--39 it was a still statistically significant 3.3% (p\<0.05), while it was 2.2% and 2.5% in the groups at 40--49 and 50--59 years of age. In all these groups the age-specific upper reference interval was lower compared to that proposed by the manufacturer. In the oldest band, 1.1% of females had TSH values above 4.94 mU/L and 7.7% had TSH values above 4.13 mU/L and below the age-specific upper reference limit calculated for that group.

We analyzed the age-specific distribution of serum thyrotropin concentrations in the population (*[Table II](#j_jomb-2018-0020_tab_002){ref-type="table"}*) by categorizing the values in four groups: lower than 0.40 (Group 1), 0.40--2.49 (Group 2), 2.50--4.00 (Group 3) and greater than 4.00 mU/L (Group 4). The TSH values progressively shifted toward higher concentrations with aging. The percentage of values in different TSH groups was significantly different among woman in the five age-related bands. The frequency of the value categorized in Group 2 continuously decreased with age, while the percentage of TSH values in the range 2.50--4.00 mU/L and greater than 4.00 mU/L continuously rose with age and was highest in the oldest group. The data suggest that the increase in the median, upper and lower reference limits, is potentially a consequence of changes in the distribution of TSH with age (*[Figure 2](#j_jomb-2018-0020_fig_002){ref-type="fig"}*).

###### 

Age specific distributions of TSH values in the selected population.

  Age group (years)   Sample   Total   Percent in TSH category (mU/L)                 
  ------------------- -------- ------- -------------------------------- ------ ------ -----
  Total               790      100     1.7                              77.2   17.3   3.8
  20--29              172      21.8    2.1                              85.6   11.3   1.0
  30--39              198      25.1    2.0                              82.3   13.6   2.1
  40--49              157      19.9    1.3                              79.8   15.7   3.2
  50--59              133      16.8    1.9                              75.2   17.6   5.3
  60--69              130      16.4    0.8                              65.4   27.6   6.2

In order to evaluate the influence of the different assays on the TFT reference values, a comparison study analyzing 80 samples using three TSH, fT4 and fT3 tests produced by different manufacturers was performed. All the samples were analyzed on the same day on each platform. For the regression analysis the thyroid hormone results from the Architect i2000 were used as a reference point and compared to the other assays (see *[Figure 3](#j_jomb-2018-0020_fig_003){ref-type="fig"}, [4](#j_jomb-2018-0020_fig_004){ref-type="fig"}* and *[5](#j_jomb-2018-0020_fig_005){ref-type="fig"}*). The assay precision for all the tests was determined by analyzing forty samples in duplicate on each analyzer. For TSH values of 0.5--5.0 mU/L, the CVs were: 1.6% for the Architect i2000, 4.1% for the Immulite 2000XP and 2.2 % for the Cobas e411 assay. In terms of the fT4 assay, the CVs for a range of values from 10 pmol/L to 20 pmol/L: were 2.2% (on the Architect i2000), 2.7% (on the Immulite 2000XP) and 2.1% (on the Cobas e411). The CVs for the fT3 values of 3.0--6.5 pmol/L were similar (2.5% on the Architect i2000 and 2.7% on the Cobas e411) except for those given by the Immulite 2000XP, on which the value was higher (5.9%).

![Comparison of TSH assays: (A) Regression lines (95% confidence interval) and (B) Bland-Altman plots with mean ± 1.96 SD limits of agreement.](jomb-38-022-g003){#j_jomb-2018-0020_fig_003}

![Comparison of fT4 assays: (A) Regression lines (95% confidence intervals) and (B) Bland-Altman plots with mean ±1.96 SD limits of agreement.](jomb-38-022-g004){#j_jomb-2018-0020_fig_004}

![Comparison of fT3 assays: (A) Regression lines (95% confidence intervals) and (B) Bland-Altman plots with mean ±1.96 SD limits of agreement.](jomb-38-022-g005){#j_jomb-2018-0020_fig_005}

The regression analyses for the TSH values in the subset of 80 samples revealed the slope of 1.16 from the Cobas e411 and 0.92 from the Immulite 2000XP compared to the Architect i2000 results (*[Figure 3A](#j_jomb-2018-0020_fig_003){ref-type="fig"}*). The Bland-Altman plots representing the relationship between the difference and the mean of three TSH assays are shown in *[Figure 3B](#j_jomb-2018-0020_fig_003){ref-type="fig"}*. A positive bias of 12.9% was observed for TSH results measured with the Architect i2000 compared to Immulite 2000XP which yielded higher results on the first platform. By contrast, bias between Architect i2000/Cobas e411 and Immulite 2000XP/Cobas e411 was negative (-11.6% and -24.5%, respectively). It is important to note that the manufacturer-proposed upper reference limits for the Immulite 2000XP and the Cobas e411 are the same (4.20 mU/L) despite the difference obtained.

In terms of the fT4 assays, the slope values were very similar to those for the TSH, 1.15 for the Cobas e411 and 0.92 for the Immulite 2000XP, when compared to the Architect i2000 analyzer (*[Figure 4A](#j_jomb-2018-0020_fig_004){ref-type="fig"}*). The Bland-Altman agreement method for fT4 assays showed the highest mean difference between Architect i2000 and Immulite 2000XP of 13.8% (*[Figure 4B](#j_jomb-2018-0020_fig_004){ref-type="fig"}*).

The correlation coefficients between fT3 concentrations in the same samples on different analyzers were low, with Abbott versus Roche giving 0.38 and Abbott versus Siemens producing 0.64, respectively (*[Figure 5](#j_jomb-2018-0020_fig_005){ref-type="fig"}*). Mean differences between three fT3 assays were -7.8%, 3.8% and 4.1% (*[Figure 5B](#j_jomb-2018-0020_fig_005){ref-type="fig"}*).

Discussion {#j_jomb-2018-0020_s_004}
==========

To the best of our knowledge this is the first study designed to establish the age-related changes in the reference intervals of thyroid function tests in the South European -- Balkan region which takes a population-based approach.

The overall reference range for TSH at 0.44 mU/L -- 4.13 mU/L was similar to one proposed in the 2012 American Association of Clinical Endocrinologists (AACE) and American Thyroid Association (ATA) guidelines for a third generation TSH assay in iodine sufficient areas (0.45 mU/L -- 4.12 mU/L) ([@j_jomb-2018-0020_ref_018]). The upper limit was very similar to the one reported in a study conducted in another part of the Balkan region (4.20 mU/L) based on the indirect estimate of reference limits ([@j_jomb-2018-0020_ref_012]), but the values for different age bands were not in agreement. The calculated upper reference interval in our study was higher with regard to the data obtained from iodine deficient areas ([@j_jomb-2018-0020_ref_014], [@j_jomb-2018-0020_ref_015]). In two studies performed in Northern Germany, at an interval of ten years, during which iodine fortification was introduced, the upper TSH reference interval shifted towards the right and the upper limit (with no significant gender differences) raised from 2.12 mU/L ([@j_jomb-2018-0020_ref_014]) to 3.29 mU/L ([@j_jomb-2018-0020_ref_015]). Taken together, this results are in accordance with the recent AACE and ATA guidelines ([@j_jomb-2018-0020_ref_018]) underlining the influence of current iodine status on the thyrotropin range.

Our reference interval for fT4 was narrower compared to that proposed by the manufacturer and in agreement with the results of the cross-sectional study (10.5--18.9 pmol/L) performed using the same method (12). The calculated fT3 2.5^th^ percentile was higher and 97.5^th^ percentile similar to those that were proposed. In a study performed in Spain ([@j_jomb-2018-0020_ref_027]), using the same method, the lower fT3 reference limit (2.27--5.18 pmol/L) was more similar to that suggested by the manufacturers, but the age selection criteria were different and the number of subjects considerably lower when compared to our study.

Different data suggest that the change in thyrotropin levels with age varies depending on the iodine status of the population. The results of our investigation are consistent with some other previously conducted large population studies in areas with adequate iodine supplementation ([@j_jomb-2018-0020_ref_006], [@j_jomb-2018-0020_ref_022], [@j_jomb-2018-0020_ref_024]), showing that the median, lower and upper reference limits of the serum thyrotropin values of female subjects continuously increased with age. Data from NHANES III show an increase in the hormone values with age in subjects with no biochemical or clinical signs of thyroid disease ([@j_jomb-2018-0020_ref_028]). The longitudinally designed study of Bremner et al, with 1212 of participants tested twice across an interval of thirteen years, has shown the association between ageing and an increase in TSH values (being significantly greater in the older population) without a significant change in fT4 concentrations ([@j_jomb-2018-0020_ref_024]). By contrast, some cross-sectional studies in populations with a mild or moderate iodine deficiency, in the absence of thyroid disease, have demonstrated a decrease in thyrotropin concentrations with aging ([@j_jomb-2018-0020_ref_014], [@j_jomb-2018-0020_ref_020], [@j_jomb-2018-0020_ref_021]). Based on this data, the iodine supplementation of the investigated population was adequate.

As previously mentioned, in a study performed in another part of the Balkan region ([@j_jomb-2018-0020_ref_012]) based on the indirect estimate of TFT reference ranges, the 97.5 percentile of the TSH values in the youngest subjects (3.82 mU/L) was higher compared to ours (3.21 mU/L). The probable causes of this are related to the different approach used in subject selection and the inclusion of subjects younger than 20 years old in the Serbian study. In our study the question related to the subject\'s medical history included a sub-question on a diagnosis or suspected case of PCOS (which usually becomes apparent in the teens or early 20s) which is associated with a high prevalence of thyroid and autoimmune thyroid conditions ([@j_jomb-2018-0020_ref_029]), so it is possible that the inclusion of a greater number of patients with this condition affected the upper thyrotropin reference level in the youngest group in the Serbian study.

By contrast to a study performed in Western Australia ([@j_jomb-2018-0020_ref_030]), we had a significantly high percentage of females in the two youngest groups classified differently when the calculated age-specific upper TSH reference limits were applied. This is probably a consequence of the different thyrotropin values used for comparison. We evaluated the manufacturer proposed upper limit (4.94 mU/L) while in the investigation of Kahapola-Arachchige et al the results were compared with a much lower »common« cut-off of 4.0 mU/L. The differences in subject selection criteria could further contribute to this discordance.

Although the definition of subclinical hypothyroidism (SCH) is still controversial, in the female population of reproductive age (20--40 years old) there is sufficient data connecting it with fertility ([@j_jomb-2018-0020_ref_002], [@j_jomb-2018-0020_ref_003], [@j_jomb-2018-0020_ref_031], [@j_jomb-2018-0020_ref_032]). Our findings suggesting that the upper TSH reference level for the general population is slightly too high and that the use of an age-related upper limit for this population would be of interest.

In our oldest group, a significant percentage of patients would have been misclassified as hypothyroid if the upper TSH limit specific to that age group had not been applied. The results of various different studies ([@j_jomb-2018-0020_ref_005], [@j_jomb-2018-0020_ref_023], [@j_jomb-2018-0020_ref_033]) are consistent with our data, demonstrating that higher concentrations of TSH in older patients are not always an indication of the need for thyroxin treatment.

We did not find any age-related change in fT3 values. In a study conducted in southern Italy a reduction in fT3 in advanced age subjects as a result of metabolic adjustments to a lower level of oxygen consumption, was found ([@j_jomb-2018-0020_ref_034]), but since our population was comprised of females who were younger than 70 years of age it is possible that this decline was not yet noticeable.

The current data on fT4 changes with age are conflicting. In our subjects, fT4 increased with age, with values significantly higher in the two oldest cohorts compared to the younger groups. The longitudinal study in an iodine sufficient area by Bremner et al. ([@j_jomb-2018-0020_ref_024]) showed that an increase in TSH was not followed by a decrease or even a small increase in FT4 levels with age in the elderly. A Cardiovascular Health Study in a very elderly subgroup found that a serum TSH increase by 13% over 13 years of follow-up was associated with a 1.7% increase in FT4 ([@j_jomb-2018-0020_ref_035]). In a historically iodine-deficient region in the Netherlands, FT4 levels were negatively associated with age in subjects aged 35--60 and positively associated in the elderly, aged 60 or older ([@j_jomb-2018-0020_ref_036]).

TSH values distribution analysis showed that the peak frequencies shifted towards higher concentrations with age (*[Figure 2](#j_jomb-2018-0020_fig_002){ref-type="fig"}*). If the increase in the upper reference limit was a result of an increased prevalence of hypothyroidism, they would occur at the same TSH values in all groups. Therefore, the alteration of values with age, at least to some degree, represent an age-specific change in thyrotropin towards higher values, as has been found in some other studies ([@j_jomb-2018-0020_ref_006], [@j_jomb-2018-0020_ref_022]). The absence of a fall in the serum fT4 values further contributes to the evidences that the age-related rise in TSH, in populations with adequate iodine intake, is not a consequence of occult thyroid diseases, but rather of an alteration in the TSH secretion set point. If the impaired TSH bioactivity or reduced responsiveness of the thyroid gland to the hormone with age were causing higher circulating TSH values, then thyroxine concentration would not be significantly different. But the type of change in fT4 values observed in our study suggests that increased TSH secretion could be a result of the impaired sensitivity of TSH-producing cells to thyroid hormones by the down-regulation of type 2 iodothyronine deiodinase activity in the pituitary ([@j_jomb-2018-0020_ref_037]). More studies are needed to clarify the exact causes of this TSH increase with age.

For every evaluated thyrotropin assay the precision was acceptable and calibrators traceable to the WHO Second International Reference Preparation 80/558, but a bias between assays was evident. Immulite i2000 and Cobas e411 had proportional biases (with slope values of 1.16 and 0.92, respectively) compared to Architect i2000 TSH values and the Bland-Altman method showed the mean absolute difference between three methods of 11.6%, 12.9% and 24.5%. Those differences suggest that clinical guidelines should take in to account the bias between various commercial assays when »cut-off« TSH values are proposed. The proposed harmonization of thyrotropin assays may lead to the better agreement of results in the future ([@j_jomb-2018-0020_ref_038]).

The possible standardization of fT4 assays, according to an international conventional reference procedure, would change results significantly -- perhaps by as much as 80% at the upper limit of the normal range -- for some assays ([@j_jomb-2018-0020_ref_039]). The three assays compared in our study did not exhibit such a significant difference. Even the extreme absolute difference between assays described by the 95% limits of agreement did not exceed 36%. The highest fT4 between method bias of 13.8% could have an impact on the diagnosis of thyroid dysfunction, particularly if the TSH values are between the upper limit of a reference range and 10 mU/L.

The regression analyses revealed notable interassay variability in fT3 measurements in our study. Despite smaller mean differences, the Bland-Altman plots pointed out absolute extreme difference described by 95% limits of agreement exceeding 59% between the methods. Since standardization is not expected in the near future, the recommendation to measure this hormone with the same assay for follow-up should probably remain in place.

Conclusion {#j_jomb-2018-0020_s_005}
==========

In conclusion, in this selected reference female population, the serum TSH and fT4 concentrations increased with age due to modifications to the TSH set-point. The implementation of age-specific TSH reference intervals would be of interest especially for the youngest and the oldest cohort. Our results suggest the adequate iodine supplementation of the population. The impact of different TFT assays on reported values is significant (being similar to effects of age, except for fT3) and the standardization and/or harmonization of TFT remains a task of great importance. Until the realization of that goal, all measured TFT results should be evaluated in relation to population and assay specific decision limits.
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